Induction of endogenous γ-globin gene expression with decoy oligonucleotide targeting Oct-1 transcription factor consensus sequence

Journal of Hematology and Oncology

Volumn 2, Issue , 2009, Pages

  Xu, Xiaoxin S ^a   Hong, Xin ^a   Wang, Gan ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECOY OLIGONUCLEOTIDE; DNA; GAMMA GLOBIN; HEMOGLOBIN F; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 1; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CANCER CELL; CONSENSUS SEQUENCE; CONTROLLED STUDY; ERYTHROLEUKEMIA; GENE ACTIVATION; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; PROMOTER REGION; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BINDING COMPETITION; BINDING SITE; CELL STRAIN K 562; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; PATHOLOGY; REGULATORY SEQUENCE; UPREGULATION;

BINDING SITES; BINDING, COMPETITIVE; CELL SURVIVAL; CONSENSUS SEQUENCE; GAMMA-GLOBINS; GENE EXPRESSION REGULATION, LEUKEMIC; GENE TARGETING; HUMANS; K562 CELLS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; OCTAMER TRANSCRIPTION FACTOR-1; OLIGONUCLEOTIDES; PROTEIN BINDING; REGULATORY SEQUENCES, NUCLEIC ACID; UP-REGULATION;

EID: 67651167040     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-2-15     Document Type: Article

References (42)

1. Stamatoyannopoulos G, Nienhuis A, Majerus X, Varmus X: The molecular Basis of Blood diseases. Second edition. W. B. Saunders Company, Philadelphia, PA; 1994.
2. Stamatoyannopoulos G: Control of globin gene expression during development and erythroid differentiation. Exp Hematol 2005, 33:259-271.
3. Chakalova L, Carter D, Debrand E, Goyenechea B, Horton A, Miles J, Osborne C, Fraser P: Developmental regulation of the betaglobin gene locus. Prog Mol Subcell Biol 2006, 38:183-206.
4. Pace BS, Zein S: Understanding mechanisms of gamma-globin gene regulation to develop strategies for pharmacological fetalhemoglobin induction. Dev Dyn 2006, 235:1727-1737.
5. Mahajan MC, Karmakar S, Weissman SM: Control of beta globin genes. J Cell Biochem 2007, 102:801-810.
6. Yang YM, Pace B: Pharmacologic induction of fetalhemoglobin synthesis: cellular and molecular mechanisms. Pediatr Pathol Mol Med 2001, 20:87-106.
7. Wang G, Xu X, Pace B, Glazer PM, Chan P, Goodman SR, Shokolenko I: Induction of human gamma-globin gene expression via peptide nucleic acids (PNAs). Nucleic Acids Res 1999, 27:2806-2813.
8. Quek L, Thein SL: Molecular therapies in beta-thalassaemia. Br J Haematol 2007, 136:353-365.
9. Lisowski L, Sadelain M: Current status of globin gene therapy for the treatment of beta-thalassaemia. Br J Haematol 2008, 141:335-345.
10. Phillips K, Luisi B: The virtuoso of versatility: POU proteins that flex to fit. J Mol Biol 2000, 302:1023-1039.
11. Surrey S, Delgrosso K, Malladi P, Schwartz E: A single base change at position-175 in the 5'-flanking region of the Gγ-globin gene from a black with Gγβ+-HPFH. Blood 1988, 71:807-810.
12. Ottolenghi S, Nicolis S, Taramelli R, Malgaretti N, Mantovani R, Comi P, Giglioni B, Longinotti M, Dore F, Oggiano LEA: Sardinian G gamma-HPFH: a T-C substitution in a conserved "octamer" sequence in the G gamma-globin promoter. Blood 1988, 71:815-817.
13. Stoming TA, Stoming GS, Lanclos KD, Fei YI, Altay C, Kutlar F, Huisman THJ: An Aγ type of nondeletional hereditary persistence of fetalhemoglobin with a T->C mutation at position-175 to the cap site of the Aγ globin gene. Blood 1989, 73:329-333.
14. Xu X, Glazer PM, Wang G: Activation of human γ-globin gene expression via triplex-forming oligonucleotide (TFO) - directed mutations in the γ-globin gene 5' flanking region. Gene 2000, 242:219-228.
15. Gambari R: New trends in the development of transcription factor decoy (TFD) pharmacotherapy. Curr Drug Targets 2004, 5:419-430.
16. Cutroneo KR, White SL, Chiu JF, Ehrlich HP: Tissue fibrosis and carcinogenesis: divergent or successive pathways dictate multiple molecular therapeutic targets for oligo decoy therapies. J Cell Biochem 2006, 97:1161-1174.
17. Isomura I, Morita A: Regulation of NF-kappaB signaling by decoy oligodeoxynucleotides. Microbiol Immunol 2006, 50:559-563.
18. Tomita N, Kashihara N, Morishita R: Transcription factor decoy oligonucleotide-based therapeutic strategy for renal disease. Clin Exp Nephrol 2007, 11:7-17.
19. Edwards MR, Bartlett NW, Clarke D, Birrell M, Belvisi M, Johnston SL: (2009) Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther 2009, 121:1-13.
20. Eller MS, Yaar M, Ostrom K, Harkness DD, Gilchrest BA: A role for interleukin-1 in epidermal differentiation: regulation by expression of functional versus decoy receptors. J Cell Sci 1995, 108:2741-2746.
21. Sharma HW, Perez JR, Higgins-Sochaski K, Hsiao R, Narayanan R: Transcription factor decoy approach to decipher the role of NF-kappa B in oncogenesis. Anticancer Res 1996, 16:61-69.
22. Tomita N, Horiuchi M, Tomita S, Gibbons GH, Kim JY, Baran D, Dzau VJ: An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro. Am J Physiol 1998, 275:278-284.
23. Shiratsuchi T, Ishibashi H, Shirasuna K: Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines. J Cell Physiol 2002, 193:340-348.
24. Wang LH, Yang XY, Zhang X, Mihalic K, Xiao W, Farrar WL: The cis decoy against the estrogen response element suppresses breast cancer cells via target disrupting c-fos not mitogenactivated protein kinase activity. Cancer Res 2003, 63:2046-2051.
25. Novak EM, Metzger M, Chammas R, da Costa M, Dantas K, Manabe C, Pires J, de Oliveira AC, Bydlowski SP: Downregulation of TNF-alpha and VEGF expression by Sp1 decoy oligodeoxynucleotides in mouse melanoma tumor. Gene Ther 2003, 10:1992-1997.
26. Penolazzi L, Borgatti M, Lambertini E, Mischiati C, Finotti A, Romanelli A, Saviano M, Pedone C, Piva R, Gambari R: Peptide nucleic acid-DNA decoy chimeras targeting NF-kappaB transcription factors: Induction of apoptosis in human primary osteoclasts. Int J Mol Med 2004, 14:145-152.
27. Borgatti M, Boyd DD, Lampronti I, Bianchi N, Fabbri E, Saviano M, Romanelli A, Pedone C, Gambari R: Decoy molecules based on PNA-DNA chimeras and targeting Sp1 transcription factors inhibit the activity of urokinase-type plasminogen activator receptor (uPAR) promoter. Oncol Res 2005, 15:373-383.
28. Fabian RH, Perez-Polo JR, Kent TA: A decoy oligonucleotide inhibiting nuclear factor-kappaB binding to the IgGkappaB consensus site reduces cerebral injury and apoptosis in neonatal hypoxic-ischemic encephalopathy. J Neurosci Res 2007, 85:1420-1426.
29. Osako MK, Tomita N, Nakagami H, Kunugiza Y, Yoshino M, Yuyama K, Tomita T, Yoshikawa H, Ogihara T, Morishita R: Increase in nuclease resistance and incorporation of NF-kappaB decoy oligodeoxynucleotides by modification of the 3'-terminus. J Gene Med 2007, 9:812-819.
30. Tsiftsoglou AS, Wong W, Robinson SH, Hensold J: Hemin increase production of beta-like globin RNA transcripts in human erythroleukemia K-562 cells. Dev Genet 1989, 10:311-317.
31. Fibach E, Kollia P, Schechter AN, Noguchi CT, Rodgers GP: Hemininduced acceleration of hemoglobin production in immature cultured erythroid cells: preferential enhancement of fetalhemoglobin. Blood 1995, 85:2967-2974.
32. Tahara T, Sun J, Nakanishi K, Yamamoto M, Mori H, Saito T, Fujita H, Igarashi K, Taketani S: Heme positively regulates the expression of beta-globin at the locus control region via the transcriptional factor Bach1 in erythroid cells. J Biol Chem 2004, 279:5480-5487.
33. Bigler J, Eisenman RN: Isolation of a thyroid hormone-responsive gene by immunoprecipitation of thyroid hormone receptor-DNA complexes. Mol Cell Biol 1994, 14:7621-7632.
34. Weinmann AS, Farnhamm PJ: Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation. Methods 2002, 26:37-47.
35. Morishita R, Gibbons GH, Horiuchi M, Kaneda Y, Ogihara T, Dzau VJ: Role of AP-1 complex in angiotensin II-mediated transforming growth factor-beta expression and growth of smooth muscle cells: using decoy approach against AP-1 binding site. Biochem Biophys Res Commun 1998, 243:361-367.
36. Lee YN, Park YG, Choi YH, Cho YS, Cho-Chung YS: CRE-transcription factor decoy oligonucleotide inhibition of MCF-7 breast cancer cells: cross-talk with p53 signaling pathway. Biochemistry 2000, 39:4863-4868.
37. Borgatti M, Finotti A, Romanelli A, Saviano M, Bianchi N, Lampronti I, Lambertini E, Penolazzi L, Nastruzzi C, Mischiati C, Piva R, Pedone C, Gambari R: Peptide nucleic acids (PNA) -DNA chimeras targeting transcription factors as a tool to modify gene expression. Curr Drug Targets 2004, 5:735-744.
38. Cho JW, Kim JY, Kim CW, Lee KS: Down-regulation of TGF-beta1-induced type I collagen synthesis by AP-1 transcription factor decoy in scleroderma fibroblasts. J Dermatol Sci 2006, 43:207-209.
39. Bitko V, Barik S: Intranasal antisense therapy: preclinical models with a clinical future? Curr Opin Mol Ther 2007, 9:119-125.
40. Eckstein F: The versatility of oligonucleotides as potential therapeutics. Expert Opin Biol Ther 2007, 7:1021-1034.
41. Spurgers KB, Sharkey CM, Warfield KL, Bavari S: Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res 2008, 78:26-36.
42. Rayburn ER, Zhang R: Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov Today 2008, 13:513-521.